# PeptideScanner evidence objects: Efinopegdutide

Every published version of the records placed with Efinopegdutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json. Selected public evidence only; not medical advice.

- Objects: 10
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct03235219-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT03235219

> PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct03235219-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03235219-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03235219-efinopegdutide-v1
- Content SHA-256: `e0a7f569e39ec9f9b2e4c2b2f1f6e02c1c945005f2b269147ca4e9eb3e357346`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03235219 ([`ctg-observation-nct03235219-2025-04-27-03acbc41c1c9`](#source-ctg-observation-nct03235219-2025-04-27-03acbc41c1c9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03235219-2025-04-27-03acbc41c1c9`](#source-ctg-observation-nct03235219-2025-04-27-03acbc41c1c9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03235219-2025-04-27-03acbc41c1c9`](#source-ctg-observation-nct03235219-2025-04-27-03acbc41c1c9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03235219-2025-04-27-03acbc41c1c9`](#source-ctg-observation-nct03235219-2025-04-27-03acbc41c1c9))

### Sources

<a id="source-ctg-observation-nct03235219-2025-04-27-03acbc41c1c9"></a>
- **ClinicalTrials.gov record NCT03235219 · retained source version 2025-04-27:03acbc41c1c9d51180ff3e7d8137238bfc0f269ef3f35b44045f526fc7db631e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03235219) (`ctg-observation-nct03235219-2025-04-27-03acbc41c1c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03235219." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03235219-efinopegdutide-v1 SHA-256: e0a7f569e39ec9f9b2e4c2b2f1f6e02c1c945005f2b269147ca4e9eb3e357346.

---

<a id="clinicaltrials-gov-nct03546205-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT03546205

> PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct03546205-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03546205-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03546205-efinopegdutide-v1
- Content SHA-256: `700abf9c2d73db48d0f534fe0947af5e59844453622fe06dd8a934ddfe259b75`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03546205 ([`ctg-observation-nct03546205-2025-04-27-94976add2223`](#source-ctg-observation-nct03546205-2025-04-27-94976add2223))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03546205-2025-04-27-94976add2223`](#source-ctg-observation-nct03546205-2025-04-27-94976add2223))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03546205-2025-04-27-94976add2223`](#source-ctg-observation-nct03546205-2025-04-27-94976add2223))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03546205-2025-04-27-94976add2223`](#source-ctg-observation-nct03546205-2025-04-27-94976add2223))

### Sources

<a id="source-ctg-observation-nct03546205-2025-04-27-94976add2223"></a>
- **ClinicalTrials.gov record NCT03546205 · retained source version 2025-04-27:94976add22232980b361e6a6dc6fc3350a7eee86d13d376ffa5e395f534f97ed** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03546205) (`ctg-observation-nct03546205-2025-04-27-94976add2223`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03546205." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03546205-efinopegdutide-v1 SHA-256: 700abf9c2d73db48d0f534fe0947af5e59844453622fe06dd8a934ddfe259b75.

---

<a id="clinicaltrials-gov-nct03586843-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT03586843

> PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct03586843-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-04-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03586843-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03586843-efinopegdutide-v1
- Content SHA-256: `82f9cdaa273cc2984e61da698f49f4da35adb6777950aba8f57748efa637313e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03586843 ([`ctg-observation-nct03586843-2019-04-16-de87c576d57a`](#source-ctg-observation-nct03586843-2019-04-16-de87c576d57a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03586843-2019-04-16-de87c576d57a`](#source-ctg-observation-nct03586843-2019-04-16-de87c576d57a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03586843-2019-04-16-de87c576d57a`](#source-ctg-observation-nct03586843-2019-04-16-de87c576d57a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03586843-2019-04-16-de87c576d57a`](#source-ctg-observation-nct03586843-2019-04-16-de87c576d57a))

### Sources

<a id="source-ctg-observation-nct03586843-2019-04-16-de87c576d57a"></a>
- **ClinicalTrials.gov record NCT03586843 · retained source version 2019-04-16:de87c576d57ad04eee3a86b46ef97dd247a6698460bbc1e6fce8b9086de758ff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03586843) (`ctg-observation-nct03586843-2019-04-16-de87c576d57a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03586843." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03586843-efinopegdutide-v1 SHA-256: 82f9cdaa273cc2984e61da698f49f4da35adb6777950aba8f57748efa637313e.

---

<a id="clinicaltrials-gov-nct03606057-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT03606057

> PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct03606057-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-03-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03606057-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03606057-efinopegdutide-v1
- Content SHA-256: `9415dc92418f8e42af397a2f878ecce30b514caac72d006252dec79a08cfbf25`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03606057 ([`ctg-observation-nct03606057-2020-03-03-c5f32867e4ce`](#source-ctg-observation-nct03606057-2020-03-03-c5f32867e4ce))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03606057-2020-03-03-c5f32867e4ce`](#source-ctg-observation-nct03606057-2020-03-03-c5f32867e4ce))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct03606057-2020-03-03-c5f32867e4ce`](#source-ctg-observation-nct03606057-2020-03-03-c5f32867e4ce))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03606057-2020-03-03-c5f32867e4ce`](#source-ctg-observation-nct03606057-2020-03-03-c5f32867e4ce))

### Sources

<a id="source-ctg-observation-nct03606057-2020-03-03-c5f32867e4ce"></a>
- **ClinicalTrials.gov record NCT03606057 · retained source version 2020-03-03:c5f32867e4ce2032a7fa655528b08a223095493434817f1d73a5dd11b16e8dac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03606057) (`ctg-observation-nct03606057-2020-03-03-c5f32867e4ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03606057." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct03606057-efinopegdutide-v1 SHA-256: 9415dc92418f8e42af397a2f878ecce30b514caac72d006252dec79a08cfbf25.

---

<a id="clinicaltrials-gov-nct06052566-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT06052566

> PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct06052566-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06052566-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06052566-efinopegdutide-v1
- Content SHA-256: `011aa24483e4c7de12b2d18ba2d8d474580f83bfbb0298be476438946cfd3027`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06052566 ([`ctg-observation-nct06052566-2025-10-22-b1554b8fd592`](#source-ctg-observation-nct06052566-2025-10-22-b1554b8fd592))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06052566-2025-10-22-b1554b8fd592`](#source-ctg-observation-nct06052566-2025-10-22-b1554b8fd592))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06052566-2025-10-22-b1554b8fd592`](#source-ctg-observation-nct06052566-2025-10-22-b1554b8fd592))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06052566-2025-10-22-b1554b8fd592`](#source-ctg-observation-nct06052566-2025-10-22-b1554b8fd592))

### Sources

<a id="source-ctg-observation-nct06052566-2025-10-22-b1554b8fd592"></a>
- **ClinicalTrials.gov record NCT06052566 · retained source version 2025-10-22:b1554b8fd592b3c55c53adef0787f1e2478f12aab16ccffcf92f4f82a3d64bd5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06052566) (`ctg-observation-nct06052566-2025-10-22-b1554b8fd592`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06052566." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06052566-efinopegdutide-v1 SHA-256: 011aa24483e4c7de12b2d18ba2d8d474580f83bfbb0298be476438946cfd3027.

---

<a id="clinicaltrials-gov-nct06465186-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT06465186

> PeptideScanner retained ClinicalTrials.gov record NCT06465186 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct06465186-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06465186-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06465186-efinopegdutide-v1
- Content SHA-256: `875f66b9711a1f5732adc3fd13351f20fb44e3843f1245760d906720cb07f197`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06465186 ([`ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c`](#source-ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06465186 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c`](#source-ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06465186 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c`](#source-ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c`](#source-ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c))

### Sources

<a id="source-ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c"></a>
- **ClinicalTrials.gov record NCT06465186 · retained source version 2026-09-21:8a332c7b1c3c54dee1dbf3c396b3f4763f1b00dc98be381a4cc75d4a9c16eeec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06465186) (`ctg-observation-nct06465186-2026-09-21-8a332c7b1c3c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06465186." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06465186-efinopegdutide-v1 SHA-256: 875f66b9711a1f5732adc3fd13351f20fb44e3843f1245760d906720cb07f197.

---

<a id="clinicaltrials-gov-nct06482112-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT06482112

> PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct06482112-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06482112-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06482112-efinopegdutide-v1
- Content SHA-256: `94ad699d1a3d104df86195b54f2601da9ba782f6adeee8697df0430f57657f67`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06482112 ([`ctg-observation-nct06482112-2026-06-01-0d94549d811f`](#source-ctg-observation-nct06482112-2026-06-01-0d94549d811f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06482112-2026-06-01-0d94549d811f`](#source-ctg-observation-nct06482112-2026-06-01-0d94549d811f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06482112-2026-06-01-0d94549d811f`](#source-ctg-observation-nct06482112-2026-06-01-0d94549d811f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06482112-2026-06-01-0d94549d811f`](#source-ctg-observation-nct06482112-2026-06-01-0d94549d811f))

### Sources

<a id="source-ctg-observation-nct06482112-2026-06-01-0d94549d811f"></a>
- **ClinicalTrials.gov record NCT06482112 · retained source version 2026-06-01:0d94549d811f3d5713b582d654c3f76e86088a7e895f84c6ceaf82c144ade106** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06482112) (`ctg-observation-nct06482112-2026-06-01-0d94549d811f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06482112." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06482112-efinopegdutide-v1 SHA-256: 94ad699d1a3d104df86195b54f2601da9ba782f6adeee8697df0430f57657f67.

---

<a id="clinicaltrials-gov-nct06701305-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT06701305

> PeptideScanner retained ClinicalTrials.gov record NCT06701305 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct06701305-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06701305-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06701305-efinopegdutide-v1
- Content SHA-256: `3ce74633a6a5391dc751225a94daf8a6ff5da030a9efe4f92dc0baabff517233`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06701305 ([`ctg-observation-nct06701305-2025-02-26-a803811e856c`](#source-ctg-observation-nct06701305-2025-02-26-a803811e856c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06701305 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06701305-2025-02-26-a803811e856c`](#source-ctg-observation-nct06701305-2025-02-26-a803811e856c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06701305 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06701305-2025-02-26-a803811e856c`](#source-ctg-observation-nct06701305-2025-02-26-a803811e856c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06701305-2025-02-26-a803811e856c`](#source-ctg-observation-nct06701305-2025-02-26-a803811e856c))

### Sources

<a id="source-ctg-observation-nct06701305-2025-02-26-a803811e856c"></a>
- **ClinicalTrials.gov record NCT06701305 · retained source version 2025-02-26:a803811e856c89e8302ba4794ce74615ae5aff2d6b5191a72fc4b760a0268a6e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06701305) (`ctg-observation-nct06701305-2025-02-26-a803811e856c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06701305." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06701305-efinopegdutide-v1 SHA-256: 3ce74633a6a5391dc751225a94daf8a6ff5da030a9efe4f92dc0baabff517233.

---

<a id="clinicaltrials-gov-nct06836037-efinopegdutide-v1"></a>

## ClinicalTrials.gov record NCT06836037

> PeptideScanner retained ClinicalTrials.gov record NCT06836037 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.

- Evidence object: `story:clinicaltrials-gov-nct06836037-efinopegdutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06836037-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06836037-efinopegdutide-v1
- Content SHA-256: `b1a4c415fac83094490e25dfa0bb8b754bff2add04f862b419eb43188f9829ed`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06836037 ([`ctg-observation-nct06836037-2025-02-21-35465b738a09`](#source-ctg-observation-nct06836037-2025-02-21-35465b738a09))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06836037 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06836037-2025-02-21-35465b738a09`](#source-ctg-observation-nct06836037-2025-02-21-35465b738a09))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06836037 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was efinopegdutide. ([`ctg-observation-nct06836037-2025-02-21-35465b738a09`](#source-ctg-observation-nct06836037-2025-02-21-35465b738a09))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06836037-2025-02-21-35465b738a09`](#source-ctg-observation-nct06836037-2025-02-21-35465b738a09))

### Sources

<a id="source-ctg-observation-nct06836037-2025-02-21-35465b738a09"></a>
- **ClinicalTrials.gov record NCT06836037 · retained source version 2025-02-21:35465b738a09f50fb88450937d53765213390ac337e35393d046a25587a1cae1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06836037) (`ctg-observation-nct06836037-2025-02-21-35465b738a09`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06836037." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#clinicaltrials-gov-nct06836037-efinopegdutide-v1 SHA-256: b1a4c415fac83094490e25dfa0bb8b754bff2add04f862b419eb43188f9829ed.

---

<a id="pubmed-pmid-43003104-efinopegdutide-v1"></a>

## Efinopegdutide: a step towards precision in MASH therapy?

> PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43003104-efinopegdutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43003104-efinopegdutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#pubmed-pmid-43003104-efinopegdutide-v1
- Content SHA-256: `c477a4be75907769ed4b198819b15b80aa94cbd029608a47cfeb35dc7c95a3f4`

### Claims and source pins

#### Headline

Efinopegdutide: a step towards precision in MASH therapy? ([`pubmed-observation-pmid-43003104-2026-11-09-930645f05b94`](#source-pubmed-observation-pmid-43003104-2026-11-09-930645f05b94))

#### Summary

PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43003104-2026-11-09-930645f05b94`](#source-pubmed-observation-pmid-43003104-2026-11-09-930645f05b94))

#### Paragraph 1

PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43003104-2026-11-09-930645f05b94`](#source-pubmed-observation-pmid-43003104-2026-11-09-930645f05b94))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43003104-2026-11-09-930645f05b94`](#source-pubmed-observation-pmid-43003104-2026-11-09-930645f05b94))

### Sources

<a id="source-pubmed-observation-pmid-43003104-2026-11-09-930645f05b94"></a>
- **Efinopegdutide: a step towards precision in MASH therapy? · retained source version 1:2026-11-09:current:930645f05b948e3cddc7b41337a36b325a8a5a8ab4a221f26bc92c280f2f5ea9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43003104/) (`pubmed-observation-pmid-43003104-2026-11-09-930645f05b94`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Efinopegdutide: a step towards precision in MASH therapy?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efinopegdutide.json#pubmed-pmid-43003104-efinopegdutide-v1 SHA-256: c477a4be75907769ed4b198819b15b80aa94cbd029608a47cfeb35dc7c95a3f4.

